A Case Report of Ischemic Stroke in a Patient with Metastatic Gastric Cancer Secondary to Treatment with the Vascular Endothelial Growth Factor Receptor-2 Inhibitor Ramucirumab

Michael E. Christiansen, Timothy Ingall, Edward C. Lew, Ramesh K. Ramanathan, Harshita R. Paripati

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Ramucirumab is an antiangiogenesis agent targeting the vascular endothelial growth factor receptor-2 (VEGFR-2), approved to treat advanced gastric and colon cancer. In clinical trials, it was shown to cause a small increase in arterial thromboembolism compared to placebo, including cerebral and myocardial ischemia, which was not statistically significant. Detailed case reports are lacking and we here present one of the first case reports of stroke secondary to ramucirumab-induced in situ thrombosis.

Original languageEnglish (US)
Pages (from-to)317-320
Number of pages4
JournalCase Reports in Oncology
Volume9
Issue number2
DOIs
StatePublished - Jan 1 2016

Keywords

  • Adverse effects
  • Angiogenesis inhibitors
  • Gastric cancer
  • Ischemic stroke

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'A Case Report of Ischemic Stroke in a Patient with Metastatic Gastric Cancer Secondary to Treatment with the Vascular Endothelial Growth Factor Receptor-2 Inhibitor Ramucirumab'. Together they form a unique fingerprint.

  • Cite this